{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/malaria-prophylaxis/prescribing-information/doxycycline/","result":{"pageContext":{"chapter":{"id":"57e80cdf-fc37-5774-979d-f58301a7b5fb","slug":"doxycycline","fullItemName":"Doxycycline","depth":2,"htmlHeader":"<!-- begin field de74b6fe-94e2-479f-9b44-8b368fb5b44d --><h2>Prescribing doxycycline</h2><!-- end field de74b6fe-94e2-479f-9b44-8b368fb5b44d -->","summary":"","htmlStringContent":"<!-- begin item b5273a21-4356-4cc0-892c-3540e1364127 --><!-- begin field 41fc0727-81a8-469a-9298-a88e00d4723a --><ul><li><strong>Regimen</strong><ul><li>Adult and children aged 12–17 years — once daily dose should be started 1 to 2 days before entering a malarious area, continuing throughout the time in the area and for 4 weeks after leaving the area. Tablets should be swallowed whole and must not be crushed.</li></ul></li><li><strong>Contraindications</strong><ul><li>Allergy to tetracyclines or to any ingredients of the preparation.</li><li>Children under 12 years of age.</li><li>Pregnancy — use during pregnancy is contraindicated in the Summary of Product Characteristics. The UK National Teratology Information Service (UKTIS] states that doxycycline is best avoided for antimalarial prophylaxis during pregnancy. However, if required before 15 weeks' gestation it should not be withheld if other options are unsuitable. The course of doxycycline, including the 4 weeks after travel, must be completed before 15 weeks’ gestation (seek expert advice).</li><li>Breastfeeding — The Public Health England Advisory Committee on Malaria Prevention (ACMP) recommend that doxycycline should not be used in breastfeeding unless other options are unsuitable and its use is felt to be essential (seek expert advice).</li></ul></li><li><strong>Cautions</strong><ul><li>Hepatic impairment or with potentially hepatotoxic drugs.</li><li>Renal impairment.</li><li>Myasthenia gravis.</li><li>Systemic lupus erythematosus.</li><li>The prescriber should warn against excessive sun exposure and recommend an appropriate sunscreen.</li></ul></li><li><strong>Interactions</strong><ul><li>Carbamazepine, phenytoin and barbiturates — the metabolism of doxycycline is accelerated and an alternative antimalarial is advised. If this is not possible dose adjustment may be necessary.</li><li>Warfarin — tetracyclines possibly enhance the anticoagulant effect of coumarins.</li><li>Ciclosporin — doxycycline may increase the plasma concentration of ciclosporin.</li><li>Vaccines<ul><li>Oral typhoid vaccine — may reduce efficacy of oral typhoid vaccine if given simultaneously.</li></ul></li></ul></li><li><strong>Adverse effects</strong><ul><li>Gastrointestinal effects such as oesophagitis, gastritis, nausea, vomiting, abdominal pain.</li><li>Photosensitivity.</li><li>Vaginal candidiasis and vaginitis.</li><li>Benign intracranial hypertension.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Tan, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">CATMAT, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Roggelin, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">UKTIS, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">CDC, 2018</a>]</p><!-- end field 41fc0727-81a8-469a-9298-a88e00d4723a --><!-- end item b5273a21-4356-4cc0-892c-3540e1364127 -->","topic":{"id":"1dfdf856-ced9-50bb-8739-9ac597e749da","topicId":"fcbcecf9-c37c-4236-a0f0-e6ea3ff72076","topicName":"Malaria prophylaxis","slug":"malaria-prophylaxis","lastRevised":"Last revised in January 2018","chapters":[{"id":"ce4f76aa-9527-5f8c-9846-98b8c95af6e4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6fd40a83-7b55-56f4-97de-93dd8ba2ad8f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"665f9f2c-5318-56d6-ac14-83dd936bdf97","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"62945b37-6310-5a07-b2dc-90e23836e367","slug":"changes","fullItemName":"Changes"},{"id":"57a7f2b1-f3c6-5c7c-be23-60a85ca3e97f","slug":"update","fullItemName":"Update"}]},{"id":"4cbf6005-cbd7-5792-be78-1e08b1755887","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"24cd959e-2b4a-53d8-9a67-2cb6351480d4","slug":"goals","fullItemName":"Goals"},{"id":"8bfd8f1f-5162-55f5-98d0-024aa470eda3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6e3197bd-4c7e-50e3-8571-464b20b486e6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"68b0fb84-1d6e-5755-9c2e-89fd57721afa","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0e6ae722-735b-5e79-85d2-194cb8187380","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"66ce78ae-da4a-51bf-9d51-ae896236d71d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f8048c7c-b171-5f3b-91f0-2a353065712f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0f3bc680-088f-5879-bf5b-9cc85a3ea0ff","slug":"definition","fullItemName":"Definition"},{"id":"b849c9ff-c93f-5656-a227-098952e12f88","slug":"causes","fullItemName":"Causes"},{"id":"caad75c1-ac57-5c45-b040-8526b6235302","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ef83916a-1184-5356-93ba-f9bac26e167a","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a763547a-e2f3-5435-b3e5-36b2b8ad0c9e","slug":"complications","fullItemName":"Complications"}]},{"id":"254e9708-01a9-5862-801a-70f9e1fb5e84","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"3379892e-94c0-5840-a578-cb5766212c69","slug":"assessment","fullItemName":"Assessment"},{"id":"4f391cab-b5f3-563e-be8a-a7235fe6467f","slug":"clinical-features","fullItemName":"Clinical features"}]},{"id":"18712f50-06cc-5638-9851-5c50e65488b5","fullItemName":"Management","slug":"management","subChapters":[{"id":"97193dc0-631b-5bea-89f3-7e605df7f3f4","slug":"malaria-prevention-in-travellers-from-the-uk","fullItemName":"Scenario: Malaria prevention in travellers from the UK"}]},{"id":"7750a127-e87f-5079-8777-0c8f13536296","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d4c5d3cf-2088-5d0a-94a1-af0994185aa5","slug":"drug-availability-on-the-nhs","fullItemName":"Drug availability on the NHS"},{"id":"f0cf5bcc-8534-50cf-a520-0e80e777e72d","slug":"prescribing-in-children","fullItemName":"Prescribing in children"},{"id":"2f74fd56-68c0-56c8-a07c-22482e10e67e","slug":"chloroquine","fullItemName":"Chloroquine"},{"id":"a6e70a24-4baa-514f-9d3a-a7ccb0d9b45c","slug":"proguanil","fullItemName":"Proguanil"},{"id":"2ce163bd-7fa7-51bd-8554-3a6a1cafdfa1","slug":"mefloquine","fullItemName":"Mefloquine"},{"id":"4ca8c124-4f45-50ce-a3b2-9a02219d6ab9","slug":"proguanil-plus-atovaquone","fullItemName":"Proguanil plus atovaquone"},{"id":"57e80cdf-fc37-5774-979d-f58301a7b5fb","slug":"doxycycline","fullItemName":"Doxycycline"}]},{"id":"38b67274-c723-5e50-9cdd-5cc01de962cb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"91d3306b-2734-52a0-ac13-1adf3711008a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bb5bc365-9c32-5684-9333-e464e129ad67","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7b7d36b2-37d8-5815-836a-898e104a533e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2d5b97c9-c3d7-51bf-beae-65128d39bd5d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d69ddbc4-81c8-5404-8a15-7bc2502831cb","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c2fc1581-dd5f-5317-a19f-cfb72905246e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d7b5a2b6-f6a2-529e-8337-1780d8941d2c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7750a127-e87f-5079-8777-0c8f13536296","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}